Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 1.00 |
| ▸ | IL17A | Q16552 | 1/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.63 |
| ▸ | PARP1 | P09874 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30052302 | 1.00 | BRD4 (1.00) | BRD4IL17AHDAC1HDAC6HDAC3 | |
| SCHEMBL378226 | 0.99 | BRD4 (0.98) | BRD4IL17AHDAC1HDAC6HDAC3 | |
| SCHEMBL378016 | 0.99 | BRD4 (0.98) | BRD4IL17AHDAC1HDAC6HDAC3 | |
| SCHEMBL377761 | 0.98 | BRD4 (0.96) | BRD4IL17AHDAC1HDAC6HDAC3 | |
| SCHEMBL377826 | 0.95 | BRD4 (0.91) | BRD4IL17AHDAC1HDAC6HDAC3 | |
| SCHEMBL377797 | 0.95 | BRD4 (0.90) | BRD4IL17AHDAC1HDAC6HDAC3 | |
| SCHEMBL377723 | 0.94 | BRD4 (0.88) | BRD4IL17AHDAC1HDAC6HDAC3 | |
| SCHEMBL349172 | 0.92 | BRD4 (0.85) | BRD4IL17AHDAC1HDAC6HDAC3 | |
| SCHEMBL30053181 | 0.92 | BRD4 (0.85) | BRD4IL17AHDAC1HDAC6HDAC3 | |
| SCHEMBL378069 | 0.90 | BRD4 (0.81) | BRD4IL17AHDAC1HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582613-B2 | Biomimetic, reactive oxygen species-detonable nanoclusters for antirestenotic therapy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-03-24 | — | — | US | claimed |
| WO-2025054356-A1 | BET INHIBITORS FOR THE TREATMENT OF CANCER | LEAPFROG BIO, INC. (US) | 2025-03-13 | — | — | WO | claimed |
| US-12161726-B2 | Biomimetic vesicles and uses thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2024-12-10 | — | — | US | claimed |
| US-20240335392-A1 | BIOMIMETIC, REACTIVE OXYGEN SPECIES-DETONABLE NANOCLUSTERS FOR ANTIRESTENOTIC THERAPY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-10-10 | — | — | US | claimed |
| US-20240245787-A1 | E3 LIGASE BINDERS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-25 | — | — | US | claimed |
| EP-4323340-A2 | E3 LIGASE BINDERS AND USES THEREOF | President and Fellows of Harvard College (US) | 2024-02-21 | — | — | EP | claimed |
| EP-3796895-B1 | BIOMIMETIC VESICLES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-02-14 | — | — | EP | claimed |
| US-20230346972-A1 | BIOMIMETIC VESICLES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION | 2023-11-02 | — | — | US | claimed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | claimed |
| WO-2023004387-A1 | BIOMIMETIC, REACTIVE OXYGEN SPECIES-DETONABLE NANOCLUSTERS FOR ANTIRESTENOTIC THERAPY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2023-01-26 | — | — | WO | claimed |
| US-8889698-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2014-11-18 | — | — | US | claimed |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| WO-2013156869-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | WO | claimed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | claimed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | claimed |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | claimed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | claimed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | claimed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | BRD4 10/4885IL17A 4442/4885HDAC1 30/4885 |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | BRD4, BMI1, BRPF3 | BRD4 1/4885IL17A 4058/4885HDAC1 41/4885 |
| US-12582613-B2 | Biomimetic, reactive oxygen species-detonable nanoclusters for antirestenotic therapy | EXOSC10, CD47, CD63 | BRD4 1543/4885IL17A 1039/4885HDAC1 4174/4885 |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885IL17A 4740/4885HDAC1 510/4885 |
| US-20240245787-A1 | E3 LIGASE BINDERS AND USES THEREOF | XIAP, UBE3A, UBE3C | BRD4 1801/4885IL17A 932/4885HDAC1 1797/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | BRD4 693/4885IL17A 3984/4885HDAC1 1272/4885 |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | BRD4 700/4885IL17A 226/4885HDAC1 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.